A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-08
DOI
10.1002/jcph.1387
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence
- (2018) Emily Stockings et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
- (2018) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
- (2018) L. Cuñetti et al. TRANSPLANTATION PROCEEDINGS
- Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
- (2018) G. M. Mandolini et al. Epidemiology and Psychiatric Sciences
- Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice
- (2018) David Cheng et al. JOURNAL OF ALZHEIMERS DISEASE
- Labeling Accuracy of Cannabidiol Extracts Sold Online
- (2017) Marcel O. Bonn-Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group
- (2017) Harneet Hundal et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
- (2017) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cannabidiol: State of the art and new challenges for therapeutic applications
- (2017) Simona Pisanti et al. PHARMACOLOGY & THERAPEUTICS
- Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
- (2016) Evan J. Hess et al. EPILEPSIA
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
- (2016) Orrin Devinsky et al. LANCET NEUROLOGY
- Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
- (2015) Alexandra L. Geffrey et al. EPILEPSIA
- Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users
- (2015) Chandni Hindocha et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cannabinoids for Medical Use
- (2015) Penny F. Whiting et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans
- (2015) Alex F. Manini et al. Journal of Addiction Medicine
- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
- (2014) Attila Oláh et al. JOURNAL OF CLINICAL INVESTIGATION
- Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series
- (2014) M. H. N. Chagas et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
- (2014) Marcos Hortes N Chagas et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- (2013) M. Mecha et al. NEUROBIOLOGY OF DISEASE
- Cannabidiol enhances consolidation of explicit fear extinction in humans
- (2013) Ravi K. Das et al. PSYCHOPHARMACOLOGY
- A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
- (2013) Colin Stott et al. SpringerPlus
- Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
- (2012) R. Martin-Santos et al. CURRENT PHARMACEUTICAL DESIGN
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
- (2012) Amir Englund et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
- (2011) Mateus M Bergamaschi et al. NEUROPSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
- (2009) Sagnik Bhattacharyya et al. NEUROPSYCHOPHARMACOLOGY
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
- (2007) R G Pertwee BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started